Blog

L3Harris Technologies, Inc. (NYSE:LHX) is among the 10 Largest Defense Stocks in 2025. On October 20, the company announced that it had been selected by the Republic of Korea for its airborne early warning and control (AEW&C) program.

Under the contract, the firm will partner with Bombardier, Korean Air, and ELTA Systems to deliver modified Bombardier Global 6500 AEW&C aircraft for the country’s air force. The program is valued at over $2.26 billion.

The advanced aircraft fleet will operate longer and fly faster, aiding in enhancing Korea’s mission readiness. The aircraft will also cruise at higher altitudes, providing combat-proven radar coverage and improved security, which will aid in swift detection and tackling of threats. Moreover, the communications suite will offer interoperability with the US, NATO, and other allied partners, resulting in a networked battlespace.

Christopher Kubasik, Chair and CEO, at L3Harris Technologies, Inc. (NYSE:LHX) shared the following remarks on the contract award:

“L3Harris is ready to deliver an advanced aircraft fleet that will strengthen mission effectiveness for a key American ally in the Indo-Pacific region. We look forward to collaborating with the Republic of Korea to develop, test, integrate and sustain this vital capability for years to come.”

L3Harris Technologies, Inc. (NYSE:LHX) provides end-to-end technology solutions connecting the air, land, space, sea, and cyber domains in national security. The stock has delivered impressive returns in 2025, rising over 42% year-to-date as of October 23.

While we acknowledge the potential of LHX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 14 Best Big Name Stocks to Invest in Right Now and 9 Defense Stocks That Will Skyrocket

Disclosure: None.

Please chooseI’m not a medical professional.Allergy and ImmunologyAnatomyAnesthesiologyBiostatisticsCardiac/Thoracic/Vascular SurgeryCardiologyCritical CareDentistryDermatologyDiabetes and EndocrinologyEmergency MedicineEpidemiology and Public HealthFamily MedicineForensic MedicineGastroenterologyGeneral PracticeGeneticsGeriatricsHealth PolicyHematologyHIV/AIDSHospital-based MedicineI’m not a medical professional.Infectious DiseaseIntegrative/Complementary MedicineInternal MedicineInternal Medicine-PediatricsMedical Education and SimulationMedical PhysicsMedical StudentNephrologyNeurological SurgeryNeurologyNuclear MedicineNutritionObstetrics and GynecologyOccupational HealthOncologyOphthalmologyOptometryOral MedicineOrthopaedicsOsteopathic MedicineOtolaryngologyPain ManagementPalliative CarePathologyPediatricsPediatric SurgeryPharmacologyPhysical Medicine and RehabilitationPlastic SurgeryPodiatryPreventive MedicinePsychiatryPsychologyPulmonologyRadiation OncologyRadiologyRheumatologySubstance Use and AddictionSurgeryTherapeuticsTraumaUrologyMiscellaneous

JD.com (NasdaqGS:JD) is making headlines as it aims to expand into Hong Kong’s insurance sector, even as recent regulatory moves affect its digital asset projects in the region. These changes offer fresh insight into the company’s evolving strategy and challenges.

See our latest analysis for JD.com.

JD.com’s latest push into insurance comes at a pivotal moment for the stock. Despite steady innovation and expansion, momentum has faded over the past year, with shares closing at $33.19 and a -14.4% total shareholder return. Looking further back, long-term holders have faced deeper losses. Investors are now weighing how JD.com’s strategic shifts and regulatory headwinds might reshape its outlook.

Curious to see what other dynamic companies are shaking up their industries? It could be time to broaden your search and discover fast growing stocks with high insider ownership

The question now is whether JD.com’s recent share slump signals a compelling value opportunity or if the market is already factoring in the company’s future growth potential. Could this be a turning point for investors?

With the narrative’s fair value target sitting at $45.12, substantially above JD.com’s last close, there is a significant gap in how analysts and the market are currently pricing the company. This disparity is setting the stage for an intriguing debate about JD.com’s future prospects and the underlying growth story.

Diversification into high-growth and synergistic businesses, especially food delivery, general merchandise, and international retail, are driving new user cohorts, accelerating cross-selling, and establishing new revenue streams, which should underpin top-line growth and gradually improve Group-level net margins as these businesses scale.

Read the complete narrative.

Curious what’s fueling that bullish outlook? The narrative hinges on a powerful combination of revenue acceleration, margin expansion, and a future earnings multiple usually reserved for mature industry leaders. Want to know the precise projections guiding this premium price? Dive in to discover what assumptions drive the analysts’ valuation and see if they could reshape your entire perspective on JD.com.

Result: Fair Value of $45.12 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, intensifying competition in food delivery and persistent margin pressure could quickly test whether this optimistic outlook holds true for JD.com.

Find out about the key risks to this JD.com narrative.

If you’re not convinced by the consensus or want to put your own spin on the story, you can craft your own view in just a few minutes, and Do it your way.

A great starting point for your JD.com research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.

Smart investors always keep their eyes open for what’s next. Don’t let a great opportunity pass you by. Put the power of the Simply Wall St Screener to work and spot the market’s most promising ideas before the crowd catches on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include JD.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com